Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN AM DE SOUZA

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1548232820
CMS profile
114802
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,220.53

89 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,220.53 89

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN AM DE SOUZA

NPI 1548232820 · CMS profile ID 114802

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548232820?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN AM DE SOUZA, NPI 1548232820, CMS profile ID 114802. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548232820?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STEPHEN AM DE SOUZA, NPI 1548232820, CMS profile ID 114802. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548232820?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STEPHEN AM DE SOUZA, NPI 1548232820, CMS profile ID 114802, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1548232820?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

89 matching records · $2,220.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 89 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–89 of 89.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Coherus Biosciences Inc. $20.9006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060240891 CMS
Genentech USA, Inc. $7.0406/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562987 CMS
Genentech USA, Inc. $6.9205/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562961 CMS
Genentech USA, Inc. $7.9505/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040563081 CMS
Genentech USA, Inc. $6.8505/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040563091 CMS
Genentech USA, Inc. $7.4105/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562871 CMS
EyePoint Pharmaceuticals US, Inc. $24.4405/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017491635 CMS
Genentech USA, Inc. $7.4105/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562929 CMS
Genentech USA, Inc. $7.1405/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040563075 CMS
AbbVie Inc. $12.5305/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996619307 CMS
ANI Pharmaceuticals, Inc. $21.5305/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034187623 CMS
Genentech USA, Inc. $6.9005/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040563051 CMS
Genentech USA, Inc. $6.2204/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562881 CMS
EyePoint Pharmaceuticals US, Inc. $24.2504/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017490399 CMS
EyePoint Pharmaceuticals US, Inc. $19.4704/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017492907 CMS
AbbVie Inc. $17.7304/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996619303 CMS
Genentech USA, Inc. $6.2304/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040563067 CMS
Regeneron Healthcare Solutions, Inc. $31.6104/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999145799 CMS
Bausch & Lomb Americas Inc. $17.3403/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037872973 CMS
Genentech USA, Inc. $6.8303/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562969 CMS
Genentech USA, Inc. $5.7703/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562921 CMS
Genentech USA, Inc. $6.7503/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562945 CMS
Regeneron Healthcare Solutions, Inc. $30.5603/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999145791 CMS
AbbVie Inc. $12.5303/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996619299 CMS
Genentech USA, Inc. $6.5802/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040563041 CMS
Genentech USA, Inc. $6.6202/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040563061 CMS
EyePoint Pharmaceuticals US, Inc. $24.0002/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017485533 CMS
Genentech USA, Inc. $7.1902/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562913 CMS
AbbVie Inc. $32.4402/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996619295 CMS
AbbVie Inc. $14.8102/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996619291 CMS
Genentech USA, Inc. $6.7501/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562897 CMS
Rhythm Pharmaceuticals, Inc. $16.2901/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051223483 CMS
EyePoint Pharmaceuticals US, Inc. $22.0301/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017489987 CMS
AbbVie Inc. $15.8901/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996619289 CMS
Genentech USA, Inc. $6.3901/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562991 CMS
Coherus Biosciences Inc. $29.2301/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060240739 CMS
AbbVie Inc. $13.5701/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996619285 CMS
Genentech USA, Inc. $6.6401/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040562978 CMS
Genentech USA, Inc. $6.3101/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040563009 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,794.90 53
PY2020 $3,821.10 20
PY2021 $15,848.99 36
PY2022 $11,602.24 64
PY2023 $2,220.53 89
PY2024 $53,607.05 102
PY2025 $2,389.34 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $10,717.36 1
PY2025 Principal investigator $733,708.51 207
PY2024 Principal investigator $123,274.68 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

208 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $673.20 12/29/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233151
Principal investigator 1 Ocular Therapeutix, Inc. $6,222.00 12/24/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233143
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $164.02 12/23/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809557
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $120.00 12/23/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809593
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $47,790.00 12/22/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809555
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $132.68 12/18/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809591
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 12/17/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759967
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 12/17/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759969
Principal investigator 1 Boehringer Ingelheim International GmbH $55.68 12/17/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759971
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 12/17/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759983
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 12/17/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759985
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 12/17/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759987
Principal investigator 1 Ocular Therapeutix, Inc. $75.74 12/17/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233126
Principal investigator 1 Ocular Therapeutix, Inc. $450.00 12/17/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233139
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
Associated Retina Consultants - Phoenix
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229682
Principal investigator 1 Ocular Therapeutix, Inc. $7,736.00 12/12/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233109
Principal investigator 1 Ocular Therapeutix, Inc. $673.20 12/12/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233113
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 12/12/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233117
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,353.40 12/08/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809589
Principal investigator 1 Ocular Therapeutix, Inc. $673.20 12/05/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233106
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759963
Principal investigator 1 Ocular Therapeutix, Inc. $1,125.00 12/01/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233102
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 11/26/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233090
Principal investigator 1 Ocular Therapeutix, Inc. $34,388.00 11/26/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233098
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,789.00 11/24/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809553
Principal investigator 1 Ocular Therapeutix, Inc. $39,697.00 11/21/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233087
Principal investigator 1 Boehringer Ingelheim International GmbH $19.00 11/19/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759965
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $240.00 11/19/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809587
Principal investigator 1 Ocular Therapeutix, Inc. $600.00 11/19/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233074
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19.66 11/17/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809585
Principal investigator 1 Ocular Therapeutix, Inc. $38.75 11/14/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233062
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 11/12/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233058
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $104.00 11/11/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809551
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,353.40 11/05/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809583
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759961
Principal investigator 1 Ocular Therapeutix, Inc. $5,400.00 10/15/2025 Non-covered Recipient Entity
Associated Retina Consultants - Phoenix
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229670
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,152.90 10/13/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809537
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,038.40 10/13/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809539
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,152.90 10/13/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809541
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $53,341.00 10/10/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809535
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/10/2025 Non-covered Recipient Entity
Associated Retina Consultants - Phoenix
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229686
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759959
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $94,572.00 10/01/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809547
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,958.20 10/01/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809549
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 10/01/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233030
Principal investigator 1 Ocular Therapeutix, Inc. $72.29 10/01/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233034
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,353.40 09/25/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809579
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,353.40 09/25/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809581
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 09/24/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759953
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 09/24/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759955
Principal investigator 1 Boehringer Ingelheim International GmbH $139.20 09/24/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759957
Principal investigator 1 Ocular Therapeutix, Inc. $675.00 09/24/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233011
Principal investigator 1 Ocular Therapeutix, Inc. $96.53 09/24/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233018
Principal investigator 1 Ocular Therapeutix, Inc. $10,705.00 09/24/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233022
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $240.00 09/19/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809543
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.15 09/19/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809545
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,353.40 09/15/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809577
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,152.90 09/10/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809529
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,152.90 09/10/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809531
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,152.90 09/10/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809533
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $541.00 09/08/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809493
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $360.00 09/08/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809495
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,647.10 09/08/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809497
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,500.00 09/08/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809499
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,152.90 09/08/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809501
Principal investigator 1 Ocular Therapeutix, Inc. $231.00 09/05/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233001
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 09/03/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232952
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 09/03/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232955
Principal investigator 1 Ocular Therapeutix, Inc. $2,000.00 09/03/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232959
Principal investigator 1 Ocular Therapeutix, Inc. $72.29 09/03/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232968
Principal investigator 1 Ocular Therapeutix, Inc. $525.00 09/03/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232983
Principal investigator 1 Ocular Therapeutix, Inc. $1,050.00 09/03/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232987
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 09/03/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232994
Principal investigator 1 Ocular Therapeutix, Inc. $566.25 09/03/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232998
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $360.00 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809509
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $838.50 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809511
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,051.40 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809513
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,152.90 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809515
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,266.00 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809517
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $60.00 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809519
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,152.90 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809521
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,152.90 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809523
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $250.00 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809525
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.40 09/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809527
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759945
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 09/01/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809575
Principal investigator 1 Ocular Therapeutix, Inc. $13,773.00 08/27/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232931
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 08/26/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759947
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 08/26/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759949
Principal investigator 1 Boehringer Ingelheim International GmbH $27.84 08/26/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759951
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 08/26/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759981
Principal investigator 1 Ocular Therapeutix, Inc. $72.29 08/20/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232922
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.88 08/19/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809489
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,783.70 08/19/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809491
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $240.00 08/07/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809503
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $104.00 08/07/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809505
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,246.40 08/07/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809507
Principal investigator 1 Ocular Therapeutix, Inc. $29.93 08/06/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232899
Principal investigator 1 Ocular Therapeutix, Inc. $13,633.00 08/06/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232902
Principal investigator 1 Ocular Therapeutix, Inc. $14,095.00 08/06/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232915
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759943
Principal investigator 1 Ocular Therapeutix, Inc. $1,979.00 07/30/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232882
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,500.00 07/28/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809487
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $414.00 07/24/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809567
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,353.40 07/24/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809569
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,353.40 07/24/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809571
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,353.40 07/24/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809573
Principal investigator 1 Ocular Therapeutix, Inc. $12,846.00 07/23/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232878
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,077.70 07/21/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809481
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,494.60 07/21/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809483
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,755.20 07/21/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809485
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,881.70 07/18/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809477
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,210.30 07/18/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809479
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 07/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232826
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 07/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232830
Principal investigator 1 Ocular Therapeutix, Inc. $39.91 07/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232834
Principal investigator 1 Ocular Therapeutix, Inc. $338.00 07/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232838
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 07/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232842
Principal investigator 1 Ocular Therapeutix, Inc. $446.10 07/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232847
Principal investigator 1 Ocular Therapeutix, Inc. $31.88 07/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232851
Principal investigator 1 Ocular Therapeutix, Inc. $2,652.00 07/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232859
Principal investigator 1 Ocular Therapeutix, Inc. $925.00 07/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232862
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 07/11/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232819
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $104.00 07/10/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809475
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 07/09/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232815
Principal investigator 1 Ocular Therapeutix, Inc. $462.00 07/04/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232807
Principal investigator 1 Ocular Therapeutix, Inc. $750.00 07/04/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232811
Principal investigator 1 Ocular Therapeutix, Inc. $13,687.00 07/02/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232788
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759937
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 07/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759939
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 07/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759941
Recipient Ocular Therapeutix, Inc. $10,717.36 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229394
Principal investigator 1 Boehringer Ingelheim International GmbH $6.70 06/24/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759927
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 06/24/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759929
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 06/24/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759931
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 06/24/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759933
Principal investigator 1 Boehringer Ingelheim International GmbH $62.64 06/24/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759935
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 06/23/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232675
Principal investigator 1 Ocular Therapeutix, Inc. $72.29 06/23/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232684
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $149.96 06/19/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220813189
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $98.96 06/12/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809473
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $240.00 06/06/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809471
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $32.90 06/04/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809565
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $43.74 06/03/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809467
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 06/02/2025 Non-covered Recipient Entity
DocTrials, LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220809469
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759913
Principal investigator 1 Ocular Therapeutix, Inc. $34.39 05/28/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232656
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 05/27/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759925
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,591.40 05/21/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809561
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $250.00 05/21/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809563
Principal investigator 1 Ocular Therapeutix, Inc. $8,621.00 05/21/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232644
Principal investigator 1 Ocular Therapeutix, Inc. $12,846.00 05/21/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232652
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 05/14/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232637
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,776.00 05/13/2025 Non-covered Recipient Entity
DocTrials, LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220809559
Principal investigator 1 Ocular Therapeutix, Inc. $8,771.00 05/09/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232628
Principal investigator 1 Ocular Therapeutix, Inc. $375.00 05/07/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232613
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759911
Principal investigator 1 Ocular Therapeutix, Inc. $6,423.00 04/30/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232605
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 04/23/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759915
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 04/23/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759917
Principal investigator 1 Boehringer Ingelheim International GmbH $34.80 04/23/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759919
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 04/23/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759921
Principal investigator 1 Boehringer Ingelheim International GmbH $3.05 04/23/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759923
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 04/23/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759973
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 04/23/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759975
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 04/23/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759977
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 04/23/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759979
Principal investigator 1 Ocular Therapeutix, Inc. $38.58 04/18/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232597
Principal investigator 1 Ocular Therapeutix, Inc. $375.00 04/16/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232593
Principal investigator 1 Ocular Therapeutix, Inc. $2,389.00 04/11/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232589
Principal investigator 1 Ocular Therapeutix, Inc. $19.12 04/09/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232576
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 04/04/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232572
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $239.30 04/03/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813187
Principal investigator 1 Ocular Therapeutix, Inc. $25,431.00 04/02/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232563
Principal investigator 1 Ocular Therapeutix, Inc. $87.88 04/02/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232567
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 04/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759905
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759907
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 04/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759909
Principal investigator 1 Ocular Therapeutix, Inc. $3,610.00 03/28/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232768
Principal investigator 1 Ocular Therapeutix, Inc. $1,155.00 03/28/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232772
Principal investigator 1 Ocular Therapeutix, Inc. $4,005.00 03/28/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232783
Principal investigator 1 Ocular Therapeutix, Inc. $21,410.00 03/26/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232752
Principal investigator 1 Ocular Therapeutix, Inc. $825.00 03/26/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232756
Principal investigator 1 Ocular Therapeutix, Inc. $4,005.00 03/26/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232760
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 03/25/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759889
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759891
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 03/25/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759893
Principal investigator 1 Boehringer Ingelheim International GmbH $85.84 03/25/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759895
Principal investigator 1 Boehringer Ingelheim International GmbH $7.44 03/25/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759897
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 03/25/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759899
Principal investigator 1 Boehringer Ingelheim International GmbH $1.83 03/25/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759901
Principal investigator 1 Ocular Therapeutix, Inc. $31.89 03/14/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232739
Principal investigator 1 Ocular Therapeutix, Inc. $1,350.00 03/14/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232744
Principal investigator 1 Ocular Therapeutix, Inc. $44.94 03/07/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232723
Principal investigator 1 Ocular Therapeutix, Inc. $2,462.00 03/05/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232689
Principal investigator 1 Ocular Therapeutix, Inc. $18,746.00 03/05/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232693
Principal investigator 1 Ocular Therapeutix, Inc. $3,610.00 03/05/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232706
Principal investigator 1 Ocular Therapeutix, Inc. $51.87 03/05/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232715
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759887
Principal investigator 1 Ocular Therapeutix, Inc. $2,141.00 02/26/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232550
Principal investigator 1 Ocular Therapeutix, Inc. $525.00 02/26/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232554
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 02/05/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232516
Principal investigator 1 Ocular Therapeutix, Inc. $66.90 02/05/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232525
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759885
Principal investigator 1 Ocular Therapeutix, Inc. $19,269.00 01/24/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232545
Principal investigator 1 Ocular Therapeutix, Inc. $214.68 01/14/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232521
Principal investigator 1 Ocular Therapeutix, Inc. $50.84 01/13/2025 Non-covered Recipient Entity
DOCTRIALS LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250232509
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Associated Retina Consultants Admin
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759903

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $69,774.00 1
PY2023 Amount invested $21,291.23 1
PY2023 Value of interest $119,773.58 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $58,024.69 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $58,024.69 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $58,024.69 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $58,024.69 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

6 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 US Retina LLC $0.00 $69,774.00 Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1143634020
PY2023 US Retina LLC $21,291.23 $119,773.58 Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1052376461
PY2022 US Retina LLC $0.00 $58,024.69 Shares Physician Covered Recipient No dispute reported 06/30/2026 951869167
PY2021 US Retina LLC $0.00 $58,024.69 Shares Physician Covered Recipient No dispute reported 06/30/2026 856668695
PY2020 US Retina LLC $0.00 $58,024.69 Shares Physician Covered Recipient No dispute reported 06/30/2026 714310995
PY2019 US Retina LLC $0.00 $58,024.69 Shares Physician Covered Recipient No dispute reported 06/30/2026 655842182